F. Hoffmann-La Roche Co., Ltd.
The acquisition of LumiraDx’s Point of Care technology has received all necessary antitrust and regulatory approvals.
LumiraDx’s innovative Point of Care solutions complement Roche’s diagnostics portfolio across clinical chemistry, immunochemistry, coagulation, molecular and multiple disease areas.
By integrating LumiraDx, Roche furthers its goal of providing a decentralized solution that expands global access to testing in primary care settings around the world.
Basel, July 29, 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has received all necessary antitrust and regulatory approvals and has completed the acquisition of LumiraDx point-of-care technology. Roche will now begin the full integration of the company’s innovative multi-assay point-of-care platform and associated R&D, operational and commercial facilities into its global organization.
“With this acquisition, Roche complements its diagnostics portfolio with an easy-to-use platform that combines a wide range of immunoassays and clinical chemistry tests in a single instrument, with the potential to expand to molecular tests in the future. This innovative solution will enable Roche to further expand its decentralized patient care delivery and drive global access to timely, actionable diagnostic results.”
“Access to diagnostic testing is critical to healthcare delivery around the world and we believe LumiraDx’s platform and technology will help expand the availability of testing, particularly in settings such as primary care and low- and middle-income countries,” said Matt Source, CEO of Roche Diagnostics.
Véronique Amey, CEO of LumiraDx, added: “We are excited to continue this journey as part of Roche Diagnostics. Becoming an integral part of the Roche network paves the way to realize the full potential of our point-of-care technologies, improving access to local healthcare for patients around the world. We look forward to writing the next chapter in our shared efforts to make an even greater difference for patients.”
The story continues
Roche announced that it has signed an agreement to acquire LumiraDx point-of-care technology at the end of 2023.
Ongoing partnership with the Bill & Melinda Gates Foundation
As part of the acquisition, Roche will partner with the Bill & Melinda Gates Foundation to further expand the molecular diagnostic capabilities of its platform through the development of an innovative, rapid, point-of-care molecular TB test. Currently, it is estimated that more than four million people worldwide live with undiagnosed TB and, as a result, untreated TB.1 With a low-cost solution ideal for remote point-of-care diagnostics, the test aims to improve TB detection and treatment, helping to reach global epidemic control goals.
About Roche
Founded in 1896 in Basel, Switzerland as the first industrial manufacturer of branded pharmaceuticals, Roche has grown to become the world’s largest biotechnology company and a global leader in in vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics to improve and save lives around the world. We are pioneers of personalized healthcare and want to further transform the way healthcare is delivered to make a bigger impact. To deliver the best care for each and every person, we partner with many stakeholders to combine our strengths in diagnostics and pharmaceuticals with data insights from clinical practice.
Recognizing our commitment to taking a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceutical industry for the 15th consecutive year by the Dow Jones Sustainability Index. This honor reflects our efforts to improve access to healthcare together with local partners in every country where we operate.
Genentech, USA, is a wholly owned subsidiary of the Roche Group, which is the largest shareholder of Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
[1] World Health Organization (WHO) Global Tuberculosis Report 2022. Accessed May 30, 2024. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
Roche Global Media Relations
Phone: +41 61 688 8888 / Email: media.relations@roche.com
Dr. Hans Trees
Phone: +41 79 407 72 58
Sireia Urechi
Phone: +41 79 935 81 48
Natalie Altermatt
Phone: +41 79 771 05 25
Lorena Colfas
Phone: +34 620 29 25 51
Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83
Nina Mehlitz
Phone: +41 79 327 54 74
Kirti Pandey
Phone: +49 172 6367262
Yvette Pétillon
Phone: +41 79 961 92 50
Dr. Rebecca Schnell
Phone: +41 79 205 27 03
Roche Investor Relations
North American Investor Relations
Attachments